ENvue Medical, Inc.
FEED Healthcare Medical Devices
ENvue Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue fell 51.6%, EPS grew 75.8%, free cash flow grew 19.8% and total debt fell 45.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow FEED
ENvue Medical, Inc. (FEED) EV/Sales
As of 16 October 2026, ENvue Medical, Inc. (FEED) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from −7.6× (June 2015) to 190× (October 2017); the current reading is higher than 14% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.7× | — |
| FY2024 | 0.4× | — |
| FY2023 | −0.6× | — |
| FY2022 | 5.3× | (59.08%) |
| FY2022 | 13.1× | 11.91% |
| FY2021 | 11.7× | 476.18% |
| FY2021 | 2.0× | 119.30% |
| FY2020 | 0.9× | (97.85%) |
| FY2020 | 43.1× | 0.00% |
| FY2019 | 43.1× | (35.16%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.6× | (46.73%) |
| Mar 2026 | 3.1× | — |
| Dec 2025 | −0.7× | — |
| Sep 2025 | −0.4× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFSA PROFUSA, Inc. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| FEED ENvue Medical, Inc. | 0.1× |
| DYNTQ Dynatronics Corporation compare | 0.1× |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| SSKN Strata Skin Sciences, Inc. compare | 0.7× |
| THMO ThermoGenesis Holdings, Inc. compare | 0.8× |
| AFIB Acutus Medical, Inc. compare | 0.9× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)